MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Kodu・Aktsiate loetelu・Novo Nordisk A-S

Novo Nordisk A-S

Suletud

SektorTervishoid

37.42 -0.53

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

36.82

Max

37.64

Põhinäitajad
By Trading Economics
Sissetulek	6.9B 27B
Müük	3.5B 78B
P/E Sektori keskmine	10.301 66.418
Dividenditootlus	4.87
Kasumimarginaal	34.285
Töötajad	68,794
EBITDA	3.4B 37B

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+14.33% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	4.87% 2.36%

Turustatistika
By TradingEconomics
Turukapital	-99B 163B
Eelmine avamishind	37.95
Eelmine sulgemishind	37.42

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

62.63 / 69.23 Toetus ja vastupanu

Novo Nordisk A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. märts 2026, 10:13 UTC

Suurimad hinnamuutused turgudel

Hims & Hers Shares Double on Report of Wegovy Tie-Up

2. märts 2026, 10:04 UTC

Omandamised, ülevõtmised, äriostud

Novo Nordisk to Invest $510 Million in Boosting Irish Manufacturing Capacity

9. apr 2026, 12:34 UTC

Tulu

Novo Nordisk: This Applies to Wegovy(R) Injection, Not the Wegovy(R) Pill

9. apr 2026, 12:34 UTC

Tulu

Novo Nordisk: Delivery of Wegovy(R) Can Occur Within 48-Hours at Temperatures Up to 30degC

9. apr 2026, 12:31 UTC

Tulu

Novo Nordisk: Approval Could Also Improve Supply Chain Efficiency

9. apr 2026, 12:31 UTC

Tulu

Novo Nordisk: Approval Could Simplify, Lower Delivery Costs for Pharmacies, Online Partners

6. apr 2026, 17:13 UTC

Omandamised, ülevõtmised, äriostud

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. apr 2026, 13:53 UTC

Omandamised, ülevõtmised, äriostud

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. apr 2026, 11:24 UTC

Omandamised, ülevõtmised, äriostud

This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. -- Barrons.com

2. apr 2026, 08:21 UTC

Market Talk

Novo Nordisk's Obesity Pill Prescriptions Key For Shares as Eli Lilly Launches Rival -- Market Talk

1. apr 2026, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Why 2026 Is Biotech's Comeback Year -- Barrons.com

30. märts 2026, 09:59 UTC

Market Talk

Tulu

Novo Nordisk Earnings Could Be Solid, but Consensus Still Too High -- Market Talk

24. märts 2026, 18:00 UTC

Omandamised, ülevõtmised, äriostud

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

24. märts 2026, 14:25 UTC

Omandamised, ülevõtmised, äriostud

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

23. märts 2026, 11:02 UTC

Market Talk

Tulu

Novo Nordisk's Weight-Loss Pill Continues to Impress -- Market Talk

17. märts 2026, 19:01 UTC

Market Talk

Eli Lilly Outlook Seen as Too Optimistic -- Market Talk

10. märts 2026, 11:06 UTC

Uudisväärsed sündmused

Trump Soothes Market's Iran Fears. Why the -2-

10. märts 2026, 11:06 UTC

Uudisväärsed sündmused

Trump Soothes Market's Iran Fears. Why the Threat's Not Over for Stocks, Oil. -- Barrons.com

9. märts 2026, 13:37 UTC

Market Talk

Hims, Novo Nordisk Bound by Mutual Necessity -- Market Talk

9. märts 2026, 12:49 UTC

Market Talk

Hims Could See Near-Term Headwinds From Novo Partnership -- Market Talk

24. veebr 2026, 21:44 UTC

Tulu

These Stocks Are Today's Movers: AMD, Hims & Hers, Keysight, IBM, Kratos, Vir Biotechnology, Whirlpool, and More -- Barrons.com

24. veebr 2026, 19:57 UTC

Tulu

These Stocks Are Today's Movers: AMD, Hims & Hers, Keysight, IBM, Kratos, Vir Biotechnology, Whirlpool, and More -- Barrons.com

24. veebr 2026, 17:02 UTC

Tulu

These Stocks Are Today's Movers: AMD, Hims & Hers, Keysight, Novo Nordisk, IBM, Kratos, Vir Biotechnology, and More -- Barrons.com

24. veebr 2026, 15:09 UTC

Tulu

Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors. -- Barrons.com

24. veebr 2026, 12:44 UTC

Tulu

These Stocks Are Today's Movers: AMD, Home Depot, Novo Nordisk, Hims & Hers, Keysight, Vir Biotechnology, and More -- Barrons.com

24. veebr 2026, 12:06 UTC

Tulu

These Stocks Are Today's Movers: Home Depot, Novo Nordisk, Hims & Hers, IBM, BWX, Kratos, Vir, and More -- Barrons.com

24. veebr 2026, 11:59 UTC

Tulu

These Stocks Are Today's Movers: Home Depot, Novo Nordisk, Hims & Hers, IBM, BWX, Kratos, Vir, and More -- Barrons.com

24. veebr 2026, 11:59 UTC

Tulu

Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors. -- Barrons.com

24. veebr 2026, 10:29 UTC

Tulu

Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors. -- Barrons.com

24. veebr 2026, 10:15 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: FedEx, Home Depot, Apple -- WSJ

Võrdlus sarnastega

Hinnamuutus

Novo Nordisk A-S Prognoos

Hinnasiht

By TipRanks

14.33% tõus

12 kuu keskmine prognoos

Keskmine 43 USD 14.33%

Kõrge 47 USD

Madal 40 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Novo Nordisk A-S 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Novo Nordisk A-S aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

62.63 / 69.23Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.